Electrochemotherapy (ECT) is a therapy with antitumor effect, in which there is a combination of administration of chemotherapeutic drugs intravenously, or intratumorally and tumor application of short and high-intensity electric pulses [1]. This latter phenomenon, called electroporation, transitorily making the tumor cell membranes permeable, facilitates the intracellular delivery of administrated drugs (bleomycin or cisplatin), increasing their cytotoxicity, and leading to an additional cascade with final result of tumor cell death. For example, bleomycin increases its antitumor effectiveness more than 8000-fold [2].

Currently, ECT indications include local control of single and in-transit metastatic melanoma skin nodules not amenable to surgery or isolated limb perfusion or infusion, non-melanoma skin cancers, local recurrences and skin metastases from breast cancer, skin metastases from head and neck cancer unsuitable for surgery or standard therapies [3]. ECT also represents an important option in the palliative management of bleeding skin metastases by melanoma. These kinds of lesions can be very stress ful for the patients, often aggravate by ulceration and pain. ECT can play a role in the local management of these neoplastic lesions, because electroporation of the cell membrane causes significant vascular changes in the tumor region, inducing arteriolar vasoconstriction with the reduction of tissue blood perfusion and short-term cessation of bleeding and ulcerated cutaneous lesions [4].

Another application of ECT is the possibility to use the procedure as neoadjuvant treatment, in order to reduce tumor burden before surgical resection [2].

The European standard operating procedure for ECT calls attention to the technical aspects of the procedure and have established this treatment in clinical practice [5,6].

ECT has been reported as highly effective, with complete response rates between 60 and 70% and objective response rates of about 80% [4]. The treatment is safe, repeatable, associated with minimal discomfort for patients, limited toxicity and short duration of hospital stay.

Due to high effectiveness of ECT in treatment of cutaneous and subcutaneous tumors regardless of histologic origin, new ECT approaches are currently being developed for treatment of deep seat tumors like liver and bone metastases, soft tissue sarcomas, brain tumors and colorectal and esophageal tumors [7].

References

*Corresponding author: Ugo Marone, M.D, National Cancer Institute, Via Mariano Semmola, 80131–Naples-Italy, Tel: +390815903460; Fax: +390815903810; E-mail: dott.marone@virgilio.it

Received December 18, 2012; Accepted December 19, 2012; Published December 21, 2012


Copyright: © 2012 Marone U. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.